# Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

> **NCT04734210** · PHASE2 · COMPLETED · sponsor: **Surface Ophthalmics, Inc.** · enrollment: 139 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** 0.02% Betamethasone Sodium Phosphate
- **DRUG:** 0.04% Betamethasone Sodium Phosphate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04734210
- **Lead sponsor:** Surface Ophthalmics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-07
- **Primary completion:** 2022-10-12
- **Final completion:** 2022-10-12
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04734210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04734210, "Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04734210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*